In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Palvella Therapeutics, with a price target of $97.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Ritu Baral has given his Buy rating due to a combination of factors including Palvella Therapeutics’ strong financial position and promising clinical trial progress. The company has a cash runway extending into the second half of 2027, which is expected to support ongoing and upcoming trials, including the Phase 3 SELVA trial and the Phase 2 TOIVA trial.
The SELVA trial, which is a pivotal study for QTORIN rapamycin in treating MLM, has completed recruitment and is on track for data release in the first quarter of 2026. The company’s strategic focus on these trials, along with the anticipated approval in 2026, underpins the positive outlook. Additionally, the management’s guidance on cash burn and financial planning further supports the confidence in the company’s future performance.
According to TipRanks, Baral is a top 100 analyst with an average return of 34.9% and a 56.94% success rate. Baral covers the Healthcare sector, focusing on stocks such as Palvella Therapeutics, ACADIA Pharmaceuticals, and Insmed.
In another report released today, LifeSci Capital also maintained a Buy rating on the stock with a $130.00 price target.